Gongwin Biopharm Holdings Past Earnings Performance
Past criteria checks 0/6
Gongwin Biopharm Holdings's earnings have been declining at an average annual rate of -12.2%, while the Biotechs industry saw earnings growing at 15.8% annually. Revenues have been growing at an average rate of 84% per year.
Key information
-12.2%
Earnings growth rate
-9.9%
EPS growth rate
| Biotechs Industry Growth | 12.2% |
| Revenue growth rate | 84.0% |
| Return on equity | -7.9% |
| Net Margin | -430.7% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Gongwin Biopharm Holdings makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 24 | -105 | 104 | 52 |
| 31 Dec 23 | 19 | -101 | 92 | 53 |
| 30 Sep 23 | 11 | -128 | 79 | 101 |
| 30 Jun 23 | 2 | -207 | 86 | 129 |
| 31 Mar 23 | 2 | -231 | 77 | 162 |
| 31 Dec 22 | 1 | -292 | 67 | 194 |
| 30 Sep 22 | 1 | -217 | 60 | 142 |
| 30 Jun 22 | 1 | -152 | 43 | 124 |
| 31 Mar 22 | 1 | -137 | 41 | 103 |
| 31 Dec 21 | 1 | -122 | 39 | 83 |
| 30 Sep 21 | 1 | -118 | 40 | 88 |
| 30 Jun 21 | 1 | -114 | 41 | 93 |
| 31 Mar 21 | 1 | -103 | 41 | 85 |
| 31 Dec 20 | 1 | -93 | 42 | 76 |
| 30 Sep 20 | 0 | -99 | 44 | 79 |
| 30 Jun 20 | 0 | -105 | 45 | 82 |
| 31 Mar 20 | 0 | -107 | 46 | 82 |
| 31 Dec 19 | 0 | -110 | 47 | 83 |
| 30 Sep 19 | 0 | -107 | 46 | 80 |
| 30 Jun 19 | 0 | -105 | 46 | 77 |
| 31 Mar 19 | 0 | -108 | 48 | 76 |
| 31 Dec 18 | 0 | -111 | 49 | 75 |
| 30 Sep 18 | 0 | -113 | 50 | 77 |
| 30 Jun 18 | 1 | -115 | 50 | 80 |
| 31 Mar 18 | 1 | -119 | 52 | 82 |
| 31 Dec 17 | 1 | -124 | 55 | 84 |
| 30 Sep 17 | 1 | -125 | 63 | 73 |
| 30 Jun 17 | 1 | -127 | 72 | 62 |
| 31 Mar 17 | 0 | -115 | 68 | 52 |
| 31 Dec 16 | 0 | -102 | 64 | 43 |
| 30 Sep 16 | 0 | -80 | 52 | 33 |
| 30 Jun 16 | 0 | -58 | 41 | 24 |
| 31 Mar 16 | 0 | -53 | 40 | 17 |
| 31 Dec 15 | 0 | -47 | 39 | 11 |
| 31 Dec 14 | 0 | -16 | 36 | 0 |
Quality Earnings: 6617 is currently unprofitable.
Growing Profit Margin: 6617 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 6617 is unprofitable, and losses have increased over the past 5 years at a rate of 12.2% per year.
Accelerating Growth: Unable to compare 6617's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 6617 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (1.7%).
Return on Equity
High ROE: 6617 has a negative Return on Equity (-7.87%), as it is currently unprofitable.